Director, Revenue Accounting

Who We Are:

Xenon Pharmaceuticals (NASDAQ:XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team.

What We Do:

We are advancing an exciting product pipeline to address indications with high unmet medical need, including epilepsy, depression and pain. Our Phase 3 azetukalner program represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. In March 2026, we announced positive topline data from our Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS), and we anticipate submitting a New Drug Application to the Food and Drug Administration in the third quarter of 2026.

Our Phase 3 epilepsy program also includes a second FOS study, X-TOLE3, which would support regulatory submissions outside the U.S., and the X-ACKT study in primary generalized tonic-clonic seizures, which would support regulatory submissions for an additional epilepsy indication. We also have multiple Phase 3 azetukalner clinical trials underway in major depressive disorder (MDD) and bipolar depression (BPD), based on topline data from our Phase 2 X-NOVA clinical trial.

In addition, we are proud of our strong heritage in human genetics, deep understanding of ion channel biology, and expertise in novel chemistries to enable potent, selective ion channel targeting. We continue to advance an early-stage pipeline of novel therapeutic candidates, including Phase 1 studies for XEN
1701 and XEN
1720 (targeting Nav
1.7) and XEN
1120 (targeting Kv7), which are being developed for pain. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations.

About the Role:

We are seeking a Director, Revenue Accounting to join our team. This role will be a key member of the Finance department and will play a crucial role for revenue recognition and Gross‑to‑Net (GTN) accounting under ASC 606, while collaborating with key stakeholders in the Commercial organization.

The Director will establish scalable commercial accounting infrastructure, oversee pricing and top‑line analytics, support revenue guidance, and ensure SOX‑compliant controls as Xenon transitions from an R&D‑centric to a commercial‑centric company. This role partners cross‑functionally to deliver accurate revenue reporting, robust forecasting, and clear executive‑level insights into business performance and value drivers.

This role reports to the VP, Finance and is based out of Boston, MA, USA, in our Needham office. The level of the position will be commensurate with the candidate’s education and industry experience. Hybrid positions require a minimum of two onsite days per week.

• Design, implement, and maintain GTN reserve methodologies, including documentation of reasonable assumptions: commercial and government rebates, chargebacks, copay and patient assistance programs, distribution service fees, returns and other variable considerations
• Responsible for monthly close processes for revenue and GTN, including journal entries, account reconciliations, true‑ups, and variance analysis
• Manage the quarterly GTN forecasting process by ensuring alignment between Commercial revenue forecast and guidance and report against such guidance, including analysis of pricing actions, margin dynamics, and market trends
• Manage government pricing reporting and state price transparency reporting with internal stakeholders and outsourced vendor(s), and ensure appropriate compliance with regulatory requirements
• Work within finance systems to implement or enhance systems to address planning and reporting needs of commercial accounting and GTN processes
• Establish and maintain scalable data flows with 3PLs and other parties; review data provided by external parties for completeness, accuracy, and reasonable
• Build…